OBJECTIVES: The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting. METHODS: This retrospective monocentric study included patients with HER-2-negative metastatic BC, pretreated with anthracyclines and taxanes, who were referred to the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017. Patients received the same dose of eribulin as that used in the EMBRACE trial: 1.4 mg/m2 on days 1 and 8 every 21 days. RESULTS: In a total of 53 patients, 32% obtained a partial response, 11% a stable disease, and 43% a clinical benefit (CB). After a median follow-up of 36 months, median progression-free survival (PFS) was 4.7 months and median overall survival (OS) 13.53 months. Median PFS was significantly longer in patients who reported a CB compared to those with no CB, while survival outcomes (PFS and OS) were better in patients who received > 6 cycles of eribulin. Eribulin showed a good tolerability profile with acceptable toxicities, similar to those reported in EMBRACE. CONCLUSIONS: Our experience in a real-world setting confirms the activity, efficacy, and good tolerability profile of eribulin in heavily pretreated BC patients.
OBJECTIVES: The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting. METHODS: This retrospective monocentric study included patients with HER-2-negative metastatic BC, pretreated with anthracyclines and taxanes, who were referred to the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017. Patients received the same dose of eribulin as that used in the EMBRACE trial: 1.4 mg/m2 on days 1 and 8 every 21 days. RESULTS: In a total of 53 patients, 32% obtained a partial response, 11% a stable disease, and 43% a clinical benefit (CB). After a median follow-up of 36 months, median progression-free survival (PFS) was 4.7 months and median overall survival (OS) 13.53 months. Median PFS was significantly longer in patients who reported a CB compared to those with no CB, while survival outcomes (PFS and OS) were better in patients who received > 6 cycles of eribulin. Eribulin showed a good tolerability profile with acceptable toxicities, similar to those reported in EMBRACE. CONCLUSIONS: Our experience in a real-world setting confirms the activity, efficacy, and good tolerability profile of eribulin in heavily pretreated BC patients.
Authors: Murray J Towle; Kathleen A Salvato; Bruce F Wels; Kimberley K Aalfs; Wanjun Zheng; Boris M Seletsky; Xiaojie Zhu; Bryan M Lewis; Yoshito Kishi; Melvin J Yu; Bruce A Littlefield Journal: Cancer Res Date: 2010-12-02 Impact factor: 12.701
Authors: Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves Journal: Lancet Date: 2011-03-02 Impact factor: 79.321
Authors: Teresa Gamucci; Andrea Michelotti; Laura Pizzuti; Lucia Mentuccia; Elisabetta Landucci; Isabella Sperduti; Luigi Di Lauro; Alessandra Fabi; Giuseppe Tonini; Valentina Sini; Nello Salesi; Ilaria Ferrarini; Angela Vaccaro; Ida Pavese; Enzo Veltri; Luca Moscetti; Paolo Marchetti; Patrizia Vici Journal: J Cancer Date: 2014-03-20 Impact factor: 4.207
Authors: Min Ho Park; Soo Jung Lee; Woo Chul Noh; Chang Wan Jeon; Seok Won Lee; Gil Soo Son; Byung-In Moon; Jin Sun Lee; Sung Soo Kang; Young Jin Suh; Geumhee Gwak; Tae Hyun Kim; Young Bum Yoo; Hyun-Ah Kim; Min Young Kim; Ju Yeon Kim; Joon Jeong Journal: Breast Date: 2020-09-16 Impact factor: 4.380
Authors: Eslam B Elkaeed; Hayam A Abd El Salam; Ahmed Sabt; Ghada H Al-Ansary; Wagdy M Eldehna Journal: Molecules Date: 2021-12-15 Impact factor: 4.411